KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $500000.0.

  • Supernus Pharmaceuticals' Accumulated Depreciation & Amortization fell 1666.67% to $500000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $500000.0, marking a year-over-year decrease of 1666.67%. This contributed to the annual value of $80.4 million for FY2024, which is 523.81% down from last year.
  • Supernus Pharmaceuticals' Accumulated Depreciation & Amortization amounted to $500000.0 in Q3 2025, which was down 1666.67% from $500000.0 recorded in Q2 2025.
  • Supernus Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $85.5 million during Q4 2022, with a 5-year trough of $500000.0 in Q2 2025.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $800000.0 (2022), whereas its average is $20.0 million.
  • In the last 5 years, Supernus Pharmaceuticals' Accumulated Depreciation & Amortization soared by 121840.0% in 2021 and then crashed by 2500.0% in 2023.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Accumulated Depreciation & Amortization stood at $32.6 million in 2021, then surged by 162.44% to $85.5 million in 2022, then fell by 0.8% to $84.9 million in 2023, then dropped by 5.24% to $80.4 million in 2024, then tumbled by 99.38% to $500000.0 in 2025.
  • Its Accumulated Depreciation & Amortization was $500000.0 in Q3 2025, compared to $500000.0 in Q2 2025 and $20.4 million in Q1 2025.